
Sibeprenlimab, a new APRIL blocker, cuts proteinuria in IgA nephropathy.

Sibeprenlimab, a new APRIL blocker, cuts proteinuria in IgA nephropathy.

Andrew Shao, PhD, senior vice president for global regulatory and scientific affairs at Niagen Bioscience, discusses how increased consumer access to information has shifted the supplement landscape toward greater demand for clinically validated products and transparency. He highlights the critical role pharmacists play in guiding consumers toward evidence-based supplements, while emphasizing the need for stronger regulatory enforcement and industry accountability to improve trust and product quality.

MS requires interdisciplinary collaboration, including pharmacists who can support patients throughout disease management.

A preclinical mucosal C difficile vaccine clears spores and prevents recurrence in animals, hinting at new protection for high‑risk patients.

The experts express their concerns that current ACIP decisions and guidelines are not backed by "pure science."

Health-system pharmacists are reshaping care through prevention, PBM reform, and digital workflow redesign across hospitals, clinics, and retail.

Patients receiving dialysis with primary care physicians had lower rates of emergency department visits compared with those without primary care involvement.

The approval is significant for a condition that is estimated to affect fewer than 1 in 1 million individuals.

A 4-day course of a mycelium-based supplement reduced reactogenicity and sustained antibody levels for up to 6 months in COVID-naive participants.

Evolving myeloma therapies and pharmacist-led care reshape outcomes, tackling resistance, toxicity, and personalized treatment sequencing.

It’s been building for quite a while, but the dam seems to be breaking, and the 2 themes seem to be transparency and fiduciary duty.

OTC naloxone nasal sprays expand overdose rescue; pharmacists guide proper use, tackle stigma, and help communities curb opioid deaths.

A large observational study identifies U-shaped relationship between weekday sleep duration and estimated glucose disposal rate.

Ipsen discontinues tazemetostat after SYMPHONY-1 safety signals; pharmacists and FDA guide next steps for EZH2-mutant follicular lymphoma patients.

Niagen Bioscience’s NAD research, patents, and clinical trials, plus pharmacist-led supplement education to help consumers choose evidence-based vitamins and supplements.

Experts discuss guideline adoption, therapeutic advances, and team-based care.

Adherence to glucose-lowering drugs ranges from 41% to 68% depending on drug class.

Early detection and prevention reduce risks of diverse adverse drug reactions.

Look‑alike, soundalike drugs increase errors, but systems can prevent them.

To combat vaccine-related misinformation and disinformation, the speakers emphasize the importance of integrated education, community-led advocacy, and proactive outreach.

The FDA approves Bristol Myers Squibb’s deucravacitinib (Sotyktu), a first oral tyrosine kinase 2 inhibitor for active psoriatic arthritis.


Pharmacists quietly prevent medication harm, ease discharge chaos, and manage rising health care strain through unseen cognitive work.

Explore how limited FDA enforcement impacts vitamins and supplements, as pharmacists push industry transparency with independent testing, COAs, and research-backed quality.

Circulating tumor cells detected in peripheral blood may serve as a powerful prognostic biomarker in newly diagnosed multiple myeloma.

Peptide compounders face rising scrutiny as regulators and lawsuits zero in on adherence to established compounding standards.

NCPA President Kristen Riddle recaps the organization's Multiple Locations Conference.

As the spring travel season approaches, more than 30 countries appear on the CDC's circulating polio alert list.

New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.

Health systems coordinate pharmacy, payers, clinicians, labs, and electronic health record (EHR) teams to deliver ultra-high-cost gene therapies.